Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Revolution Medicines (RVMD) Cash & Equivalents (2018 - 2025)

Revolution Medicines (RVMD) has 7 years of Cash & Equivalents data on record, last reported at $383.7 million in Q4 2025.

  • For Q4 2025, Cash & Equivalents fell 29.34% year-over-year to $383.7 million; the TTM value through Dec 2025 reached $383.7 million, down 29.34%, while the annual FY2025 figure was $383.7 million, 29.34% down from the prior year.
  • Cash & Equivalents reached $383.7 million in Q4 2025 per RVMD's latest filing, up from $217.4 million in the prior quarter.
  • Across five years, Cash & Equivalents topped out at $696.1 million in Q4 2023 and bottomed at $97.7 million in Q1 2022.
  • Average Cash & Equivalents over 5 years is $291.8 million, with a median of $282.1 million recorded in 2024.
  • Peak YoY movement for Cash & Equivalents: skyrocketed 715.82% in 2021, then plummeted 72.22% in 2022.
  • A 5-year view of Cash & Equivalents shows it stood at $108.5 million in 2021, then soared by 48.77% to $161.4 million in 2022, then soared by 331.29% to $696.1 million in 2023, then dropped by 21.99% to $543.1 million in 2024, then dropped by 29.34% to $383.7 million in 2025.
  • Per Business Quant database, its latest 3 readings for Cash & Equivalents were $383.7 million in Q4 2025, $217.4 million in Q3 2025, and $402.4 million in Q2 2025.